top of page
Search

Monoclonal Antibody Nomenclature MRCP Part 1

TL;DR

Monoclonal antibodies nomenclature MRCP Part 1 is a high-yield pharmacology topic that helps you decode drug names into their target, origin, and clinical use. The naming system follows predictable patterns (target substem + source substem + “mab”), allowing rapid identification even for unfamiliar drugs. Mastering these rules improves both accuracy and speed in MRCP Part 1 MCQs. Focus especially on recognising immune (-li-) and tumour (-tu-) targets.


Why this matters

Monoclonal antibodies (mAbs) are increasingly tested in MRCP Part 1, especially within pharmacology and immunology questions. Rather than testing rote memorisation, the exam expects candidates to interpret drug names logically.

Understanding nomenclature allows you to:

  • Identify mechanism of action

  • Predict clinical indications

  • Anticipate adverse effects

  • Eliminate incorrect options in MCQs

Start with the MRCP Part 1 overview to understand how pharmacology fits into the broader exam blueprint.


Core Principles of Monoclonal Antibody Naming

Monoclonal antibodies follow a structured naming convention:

Prefix + Target Substem + Source Substem + mab

Example

  • Rituximab

    • -tu- → tumour

    • -xi- → chimeric

    • -mab → monoclonal antibody

👉 This structure allows you to decode unfamiliar drugs in exam stems.


High-Yield Breakdown (Exam Table)

Component

Meaning

Examples

Exam Clue

-mab

Monoclonal antibody

All mAbs

Always present

-li-

Immune system target

Adalimumab

Autoimmune disease

-tu-

Tumour target

Trastuzumab

Oncology

-ci-

Cardiovascular

Abciximab

Platelet inhibition

-vi-

Viral target

Palivizumab

Viral infections

-xi-

Chimeric (mouse-human)

Rituximab

↑ infusion reactions

-zu-

Humanised

Trastuzumab

Moderate immunogenicity

-u-

Fully human

Adalimumab

Lowest immunogenicity

The 5 Most Tested Subtopics

1. Target Substem Recognition

This is the highest-yield concept in MRCP Part 1.

  • -li- (immune) → rheumatoid arthritis, psoriasis

  • -tu- (tumour) → cancers

  • -ci- (cardiovascular) → antiplatelet agents

  • -vi- (viral) → antiviral monoclonals

👉 Exam tip: Autoimmune disease stem → likely -li-

2. Source Substem (Humanisation)

Determines immunogenicity:

  • -xi- → chimeric → higher allergic reactions

  • -zu- → humanised → moderate

  • -u- → fully human → lowest risk

👉 Clinical link: Infusion reactions are common with -xi- drugs

3. Mechanism of Action Deduction

Even unfamiliar drugs can be decoded:

  • Infliximab → TNF inhibitor → immune-mediated disease

  • Bevacizumab → VEGF inhibitor → oncology

👉 Pattern recognition is key for MRCP Part 1 success

4. Frequently Tested Drugs

  • Rituximab → CD20 → lymphoma

  • Trastuzumab → HER2 → breast cancer

  • Adalimumab → TNF-alpha → rheumatoid arthritis

  • Abciximab → GP IIb/IIIa → antiplatelet

👉 These repeatedly appear in exam questions

5. Adverse Effect Patterns

  • TNF inhibitors → TB reactivation

  • HER2 inhibitors → cardiotoxicity

  • Chimeric antibodies → infusion reactions

👉 Always link mechanism to side effects

10 High-Yield Exam Points

  1. All monoclonal antibodies end in -mab

  2. Target substem predicts organ/system involved

  3. Source substem predicts immunogenicity

  4. -li- = immune system (very common in MRCP)

  5. -tu- = tumour (oncology questions)

  6. -xi- drugs → higher hypersensitivity risk

  7. Fully human (-u-) drugs → safer profile

  8. TNF inhibitors require TB screening

  9. HER2 inhibitors require cardiac monitoring

  10. Naming allows identification of unknown drugs

Medical student practising MRCP Part 1 pharmacology using online question bank and notes

Practical Examples / Mini-Case

MCQ: A 60-year-old man with non-Hodgkin lymphoma is treated with rituximab. Which feature best describes this drug?

A. Fully human antibodyB. Targets viral proteinsC. Chimeric monoclonal antibodyD. Acts on plateletsE. Used in cardiovascular disease

Answer: C. Chimeric monoclonal antibody

Explanation:

  • Rituximab contains -xi- → chimeric

  • -tu- → tumour target

  • Therefore, used in lymphoma with higher risk of infusion reactions


Common Pitfalls (Top 5)

  • Confusing -li- (immune) with -tu- (tumour)

  • Ignoring source substem (important for adverse effects)

  • Assuming all monoclonal antibodies are fully human

  • Memorising drugs without understanding naming logic

  • Missing TB screening in TNF inhibitor questions


Practical Study Checklist

✔ Learn the naming structure (target + source + mab)✔ Memorise key substems (-li-, -tu-, -ci-, -vi-)✔ Associate source substems with immunogenicity✔ Practise decoding unfamiliar drugs✔ Link each drug class to one major adverse effect✔ Attempt timed practice via Start a mock test✔ Reinforce concepts using Free MRCP MCQs

👉 Cross-link suggestion: Pair this with a pharmacology review such as https://www.crackmedicine.com/blog/pharmacology-high-yield-mrcp-part-1/ for integrated learning.


FAQs

1. How are monoclonal antibodies named in MRCP Part 1?

They follow a structured format: prefix + target substem + source substem + “mab”. This helps identify function and origin.

2. What does “-li-” mean in monoclonal antibody names?

“-li-” indicates the immune system. These drugs are commonly used in autoimmune conditions like rheumatoid arthritis.

3. Which monoclonal antibodies are least immunogenic?

Fully human antibodies (ending in “-u-”) have the lowest immunogenicity and fewer infusion reactions.

4. Why is this topic important for MRCP Part 1?

It allows you to decode unfamiliar drugs quickly, improving accuracy without memorising every medication.

5. What is the most common exam mistake?

Confusing substems (e.g., immune vs tumour) and ignoring source substems that determine side effects.


Ready to start?

Improve your pharmacology performance in MRCP Part 1 with structured practice:

Consistent exposure to exam-style questions is the fastest way to master this topic.


Sources

 
 
 

Comments

bottom of page